Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 25Lymphoma 13Leukemia, Myeloid, Acute 10Ovarian Neoplasms 9Neoplasm Metastasis 9Lymphoma, Follicular 9Leukemia 9Stomach Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Renal Cell 8Breast Neoplasms 8Neuroblastoma 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, B-Cell, Marginal Zone 6Multiple Myeloma 5Lymphoma, Large B-Cell, Diffuse 5Kidney Neoplasms 5Hodgkin Disease 5Burkitt Lymphoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Triple Negative Breast Neoplasms 4Recurrence 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Lymphoma, Large-Cell, Immunoblastic 4

Interventions

Ipilimumab 10Nivolumab 9Interleukin-2 5Cyclophosphamide 5pembrolizumab 3incomplete Freund's adjuvant 3fludarabine phosphate 3Radiosurgery 3Melphalan 3ADI PEG20 3sotrastaurin 2fludarabine 2Specimen Handling 2Ranibizumab 2Magnetic Resonance Spectroscopy 2MART-1 Antigen 2CTLA-4 Antigen 2Biopsy 2utomilumab 1tocilizumab 1siremadlin 1sargramostim 1ruxolitinib 1relatlimab 1pentetreotide 1obinutuzumab 1montanide ISA 51 1lifileucel 1gp100 Melanoma Antigen 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uveal Melanoma × aldesleukin × Clear all
NCT03068624 2024-01-25

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

M.D. Anderson Cancer Center

Phase 1 Unknown
34 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡